Crinetics Pharmaceuticals, Inc. — Form 8-K
Filed July 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 23/100
What the filing says
Crinetics filed an 8-K on 2026-07-10 reporting entry into a material definitive agreement (Item 1.01) and changes to officer compensation or director/officer changes (Item 5.02). No specific counterparties, dollar amounts, deal terms, or personnel details are provided in the filing header or accessible document metadata.
Why this rating
Without concrete deal terms, counterparty names, or dollar figures, cannot assess materiality. Header discloses only that items were triggered; substance unavailable in excerpt.
Extracted items
- 1.01 material agreement
- 5.02 exec change
See more from July 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.